title: Use of genetic data to guide therapy in arterial disease.
abstract: There is considerable interindividual variation in the response to antiplatelet and anticoagulant therapies. It has been proposed that this variability in drug response may be attributable to genetic variants. Thus, pharmacogenetics may help to accurately predict response to cardiovascular disease (CVD) therapies in order to maximize drug efficacy, minimize drug toxicity, and to tailor personalized care for these patients. Although the clinical utility of pharmacogenetics is promising, its adoption in clinical practice has been slow. This resistance may stem from sometimes conflicting findings among pharmacogenetic studies. Thus, this review focuses on the genetic determinants of commonly used platelet antagonists and anticoagulants including aspirin, clopidogrel, dabigatran, and warfarin. We also explore the clinical translation of pharmacogenetics in the management of patients with CVD.
authors.affiliation: Population Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada.|Department of Clinical Epidemiology & Biostatistics, Population Genomics Program, McMaster University, Hamilton, ON, Canada.|Population Genomics Program, Chanchlani Research Centre, McMaster University, Hamilton, ON, Canada.
authors.forename: S
authors.initials: S
authors.lastname: Ross
authors.affiliation: Population Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada.|Department of Pathology & Molecular Medicine, McMaster University, Hamilton, ON, Canada.
authors.forename: S
authors.initials: S
authors.lastname: Nejat
authors.affiliation: Population Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada.|Department of Clinical Epidemiology & Biostatistics, Population Genomics Program, McMaster University, Hamilton, ON, Canada.|Population Genomics Program, Chanchlani Research Centre, McMaster University, Hamilton, ON, Canada.|Department of Pathology & Molecular Medicine, McMaster University, Hamilton, ON, Canada.|Thrombosis & Atherosclerosis Research Institute, Hamilton Health Sciences & McMaster University, Hamilton, ON, Canada.
authors.forename: G
authors.initials: G
authors.lastname: Paré
mesh_terms: D000818:Animals; D000925:Anticoagulants / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001711:Biotransformation; D002318:Cardiovascular Diseases / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D004351:Drug Resistance; D005838:Genotype; D006801:Humans; D010597:Pharmacogenetics; D010641:Phenotype; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D057285:Precision Medicine; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors
keywords: anticoagulants; cardiovascular diseases; genetics; pharmacogenetics; platelet aggregation inhibitors